Improvements In Work Productivity Following Baricitinib Treatment In Patients With Moderate-To-Severe Atopic Dermatitis: Results From Breeze-Ad5

Lawrence F. Eichenfield,Emanual Maverakis,Jerry Tan,Lorne Albrecht,Andrew Buchanan,Amy M. Delozier,Jinglin Zhong,Luna Sun, David Rosmarin

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2021）

Cited 1|Views11

No score

Abstract

Introduction: Baricitinib is an oral, selective Janus kinase (JAK)1/JAK2 inhibitor under investigation for treatment of moderate-to-severe atopic dermatitis (AD). This analysis examines baricitinib’s impact on workplace and daily activity.

Translated text

Key words

baricitinib treatment,work productivity,moderate-to-severe

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined